<DOC>
	<DOCNO>NCT02971202</DOCNO>
	<brief_summary>The purpose study determine key factor influence insulin sensitivity type 1 diabetes ( T1DM ) maturity onset diabetes young , type 2 ( MODY2 ) . Our study test hypothesis decrease insulin sensitivity primarily drive chronically elevate insulin level blood rather chronic elevation blood sugar .</brief_summary>
	<brief_title>Contribution Hyperinsulinemia vs. Hyperglycemia Insulin Resistance Type 1 Diabetes Maturity Onset Diabetes Young , Type 2 ( MODY2 )</brief_title>
	<detailed_description>This research determine whether insulin resistance ( IR ) T1DM predominantly effect chronic hyperglycemia , commonly accept , consequence iatrogenic hyperinsulinemia peripheral circulation , alternatively hypothesize . IR consistent under-recognized finding T1DM . Despite independent contribution micro- macrovascular disease , underlie cause establish strategy mitigate develop . This research also characterize IR maturity onset diabetes young , type 2 ( MODY2 ) , population IR inadequately study date . Insulin therapy T1DM attempt achieve euglycemia `` unphysiologic '' way , deliver insulin subcutaneous tissue compare physiologic delivery directly hepatic portal circulation . Although life-saving , peripheral insulin delivery T1DM result loss normal insulin distribution ; physiologic state maintains insulin 3-fold high concentration portal circulation compare peripheral circulation . IR T1DM could therefore occur response peripheral hyperinsulinemia , mechanism would protect hypoglycemia ensure adequate glucose delivery central nervous system . MODY2 condition result mutation gene encode glucokinase ( GCK ) , turn cause defect Î²-cell sensitivity glucose due reduce glucose phosphorylation . This effectively raise `` set point '' insulin secretion response increase glycemia . Because MODY2 patient retain pancreatic insulin secretion , usually require insulin therapy normal insulin distribution portal peripheral circulation . We therefore hypothesize IR T1DM 1 ) homeostatic response increase peripheral insulin concentration result peripheral insulin delivery significantly attributable hyperglycemia 2 ) result primarily peripheral tissue IR ( especially muscle ) primarily hepatic IR . Further , anticipate patient MODY2 , population hyperglycemia without hyperinsulinemia , insulin sensitivity similar otherwise healthy , nondiabetic individual . To test hypothesis , hyperinsulinemic , euglycemic clamp use assess IR cross-sectional study 3 group subject : 1. non-diabetic control subject , 2. patient well control T1DM , 3. patient MODY2 Key metabolic difference 3 group enable u parse relative contribution peripheral hyperinsulinemia vs. hyperglycemia IR T1DM MODY2 . Further , propose research provide information whether novel therapeutic strategy restore normal portal peripheral insulin distribution normalize insulin sensitivity ( e.g . hepatopreferential insulin analog , intraperitoneal insulin delivery ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>Inclusion criterion subject : BMI 2028 kg/m^2 Additional inclusion criterion T1DM subject : Age 1335 T1DM duration 120 year HbA1c 6.08.0 % Additional inclusion criterion MODY2 subject : age 1335 positive GCK genetic sequencing HbA1c 6.08.0 % Additional inclusion criterion control subject : age 1835 HbA1c &lt; 5.5 % Exclusion criterion subject : severe hypoglycemia ( &gt; = 1 episode past 3 month diagnosis hypoglycemia unawareness ) diabetes comorbidities ( &gt; = 1 trip emergency department poor glucose control past 6 month , New York Heart Association Class IIIV cardiac functional status , systolic blood pressure &gt; 140 diastolic blood pressure &gt; 100 mmHg , fast triglyceride &gt; 400 mg/dL , liver transaminase &gt; 2 time upper limit normal , renal transplantation serum creatinine &gt; 1.5 mg/dL ) confound medication ( systemic glucocorticoid , antipsychotic , atenolol , metoprolol , propranolol , niacin , thiazide diuretic , oral contraceptive pill &gt; 35 mcg ethinyl estradiol , growth hormone , immunosuppressant , antihypertensive , anyantilipidemic ) pregnancy Tanner stage &lt; 5 Additional exclusion criterion T1DM subject diabetes medication except insulin fast cpeptide &gt; 0.7 ng/mL</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>o-glcnacylation</keyword>
	<keyword>hexosamine</keyword>
</DOC>